Be the first person to write a business review for CSL Behring, LLC

CSL Limited is a biopharmaceutical company engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates in three segments: CSL Behring, which is engaged in manufacturing, marketing and developing plasma products; Intellectual Property Licensing, which is engaged in licensing to unrelated third parties of intellectual property generated by the Company, and Other Human Health, which comprises CSL Bioplasma and CSL Biotherapies. These businesses manufacture and distribute biotherapeutic products. It operates in Australia, United States, Switzerland and Germany.

Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

CXR Biosciences Ltd. company was founded in 2001 and is based in Dundee, the United Kingdom. CXR Biosciences Ltd. provides drug development solutions and investigative toxicology services. Its drug development solutions include bioavailability, patient response variation, drug/drug interactions, drug reactions, toxicity, reactive metabolites, customized assay development, and anticancer drug development services. The company also offers mechanistic toxicology, collaborative research, and microarray services. In addition, it provides various preclinical screening systems that include Hepatic Reductase Null, which is used for determining the role of hepatic P450 metabolism in drug disposition; ToxReporter Mice for the mechanistic assessment of potential toxic effects in vivo; antioxidant response elements; ToxReporter cell lines for drug safety screening; and nuclear hormone receptor transactivation assays. Further, the company licenses its products.

CyBio just might supplant the underpaid laboratory research assistant, so efficient are its automated systems; in all, the company makes it easier for laboratory scientists to focus on research and less on the repetitive processes involved therein. CyBio develops, produces, and markets technology platforms for drug discovery. With more than 15 years of experience in the field, CyBio provides the tools for pharmaceutical and agrochemical research, including pipetting instruments for liquid handling, incubating, and replicating, as well as software and system integration, for automated screening and reading.

Cyclacel Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.